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With their capability to undergo unlimited self-renewal and to differentiate into all cell types in the body, induced
pluripotent stem cells (iPSCs), reprogrammed from somatic cells of individual patients with defined factors, have
unlimited potential in cell therapy and in modeling complex human diseases. Significant progress has been
achieved to improve the safety of iPSCs and the reprogramming efficiency. To avoid the cancer risk and
spontaneous reactivation of the reprogramming factors associated with the random integration of viral vectors into
the genome, several approaches have been established to deliver the reprogramming factors into the somatic cells
without inducing genetic modification. In addition, a panel of small molecule compounds, many of which targeting
the epigenetic machinery, have been identified to increase the reprogramming efficiency. Despite these progresses,
recent studies have identified genetic and epigenetic abnormalities of iPSCs as well as the immunogenicity of some
cells derived from iPSCs. In addition, due to the oncogenic potential of the reprogramming factors and the
reprogramming-induced DNA damage, the critical tumor suppressor pathways such as p53 and ARF are activated
to act as the checkpoints that suppress induced pluripotency. The inactivation of these tumor suppression
pathways even transiently during reprogramming processes could have significant adverse impact on the genome
integrity. These safety concerns must be resolved to improve the feasibility of the clinic development of iPSCs into
human cell therapy.Somatic nuclear reprogramming
The pluripotent cells in the inner cell mass (ICM) are
able to differentiate into each cell type of the three germ
layers [1], and give rise to embryonic stem (ES) cell lines
[2,3]. Considering their unlimited self-renewal capability
and pluripotency to differentiate into all cell types in the
body, human pluripotent stem cells (hESCs) hold great
promise in human cell therapy. However, one major
drawback of the hESC-based cell therapy is the allogenic
immune rejection of hESC-derived cells by the recipi-
ents. While persistent systemic immune suppression
could prevent the rejection of the allogenic hESC-
derived cells, the long-term immunosuppression has ser-
ious side effects such as the increased risk for cancer
and infection [4]. Therefore, it would be highly desirable
to develop pluripotent cells with the same genetic
makeup as the patients, as the cells derived from the
patient-specific pluripotent cells are considered autolo-
gous and thus can be transplanted without the risk of
immune rejection.* Correspondence: yangxu@ucsd.edu
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reproduction in any medium, provided the orWhile it had been assumed that differentiating cells
gradually lose their plasticity during development and
the terminally differentiated cells could not give rise to
another cell type, this assumption has been challenged
by the discovery of nuclear reprogramming that allows
the switch of cell identity from one cell type to another.
Somatic nuclear reprogramming to convert a somatic
nucleus into the pluripotent state was first described in
1950s when researchers transferred nuclei from amphib-
ian blastula into enucleated eggs, resulting in adult indi-
viduals [5,6]. In subsequent experiments, this somatic
cell nuclear transfer (SCNT) technology could achieve
the same results with the nucleus from more differen-
tiated cells such as intestinal cells and skin cells [7,8].
One of the most exciting developments in the somatic
nuclear reprogramming is the first success in mamma-
lian SCNT in 1997 to produce the cloned sheep Dolly
by transferring the nuclei of adult mammary gland cells
into enucleated eggs [9]. Since then, SCNT has been
successfully applied to many other mammalian species,
including mice and nonhuman primate [10-16]. Success-
ful SCNT in human has recently been reported [17]. In
this context, the nucleus from human somatic cells can be
reprogrammed into pluripotent state after transferringal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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be retained for the derivation of pluripotent stem cells
from the cloned embryos. In summary, these results dem-
onstrate that the somatic genome has the potential to be
reprogrammed into pluripotent state.
The efficiency of SCNT to generate cloned embryos
declines dramatically when the nucleus is derived from
more differentiated cells [18]. In addition, the cloned
animals often exhibit phenotypic and genetic abnormal-
ities [15,19-21]. Another approach for somatic nuclear
reprogramming is through cell fusion when the nucleus
of the one fusion partner can be reprogrammed into the
epigenetic state of the other fusion partner [22]. In this
context, when fused with pluripotent stem cells, the nu-
cleus of the somatic cells can be reprogrammed into the
pluripotent state. For example, the fusion of thymocytes
with embryonic carcinoma cells (ECCs) could generate
immortalized pluripotent cell lines [23,24], and the
resulting hybrid cells acquired the properties of ECCs
[25,26]. Similarly, the fusion of mouse ES cells with thy-
mocytes can lead to pluripotent hybrid cells [27-29]. In
addition, the fusion of the human somatic cells with
hESCs generates pluripotent hybrid cells, and the over-
expression of Nanog can enhance such reprogramming
efficiency [30,31]. While these studies further confirm
the feasibility to reprogram somatic nucleus into pluri-
potent state, the presence of two sets of genome in the
hybrid cells remains an obstacle for any application of
these pluripotent stem cells.
Due to the technical difficulties and the ethic concerns
with the usage of human eggs, it remains a major chal-
lenge to generate human patient’s specific pluripotent
stem cells. The groundbreaking discovery of the induced
pluripotency with defined factors by Yamanaka and collea-
gues has revolutionized the field of somatic nuclear repro-
gramming. By screening two dozens factors that are
expressed in ESCs, they discovered that the combination
of four transcription factors (Oct4, Sox2, Klf4 and c-Myc)
could reprogram mouse fibroblasts into pluripotent stem
cells, termed induced pluripotent stem cells (iPSCs) [32].
Like ESCs, iPSCs are capable of unlimited self-renewal
and can differentiate into each cell type of the three germ
layers. Soon afterwards, the iPSC technology was used
successfully to reprogram somatic cells from a rapidly
growing list of species into iPSCs, including human [33-
35], monkey [36], rat [37]. In addition, somatic cells can
also be reprogrammed into iPSCs with different combina-
tions of reprogramming factors [34,38]. Even the termin-
ally differentiated cells can be successfully reprogrammed
into iPSCs, although the efficiency is much lower than the
reprogramming of precursor cell types [39-41]. The dis-
covery of iPSC technology greatly improves the feasibility
in developing patient-specific cell therapy and provides
the unique opportunity in modeling human diseases.Progress in iPSC biology
The initial reprogramming factors discovered by
Yamanaka and colleagues are Oct4, Sox2, Klf4 and
c-Myc, which can reprogram somatic cells of various
species into iPSCs [32,33]. Another set of reprogram-
ming factors (Oct4, Sox2, Nanog, and Lin28) can also
reprogram mouse and human somatic cells into iPSCs
[34,42]. c-Myc is a potent oncogene [43]. Therefore, to
reduce the oncogenic potential of iPSCs, c-Myc can be
excluded from the reprogramming cocktail but with
much lower efficiency [37,44-49]. The requirement for
various reprogramming factors depends on the progeni-
tor cell types. For example, Oct4 and Sox2 alone are suf-
ficient to reprogram the cord blood cells into iPSCs [50].
Oct4 and Klf4 alone are sufficient to reprogram adult
mouse neural stem cells and dermal papilla cells into
iPSCs [51,52]. Oct4 alone is sufficient to reprogram the
neural stem cells into iPSCs possibly due to the high
level of endogenous expression of the other reprogram-
ming factor such as Sox2 [53,54].
Beside Oct4, Sox2, Klf4 and c-Myc or Nanog, and
Lin28, there are other modulators that can either
substitute for or work together with them to improve
reprogramming efficiency (Table 1). Indeed, these modu-
lators are divided into several categories. One group falls
into transcription factors. Orphan nuclear receptor such
as Esrrb [55] and Nr5a2 [56] could replace Klf4 and
Oct4 respectively and mediate reprogramming of MEFs.
Other transcription factors like Sall4 [57], CCAAT/
enhancer-binding-protein-α (C/EBPα) [58], UTF-1, an
ESC-specific transcription factor increases reprogram-
ming efficiency [59] are also reported to improve repro-
gramming. Another class comprises cell signaling and
proliferation modulators. Overexpress SV40 large T anti-
gen (SV40 LT) [60] or human telomerase (hTERT) [61],
two proteins that promote proliferation in MEFs greatly
increased the reprogramming efficiency. Some micro-
RNAs function as cell cycle regulators also influence re-
programming [62,63]. It has been reported that TGFβ,
bone morphogenetic proteins (BMPs) and Wnt signaling
pathways could also modulate reprogramming [64-68].
Epigenetic regulators are the other subfamily. Histone
deacetylase [69-71], methyltransferase [72] and DNA
methyltransferase [73,74] have been implicated to influ-
ence reprogramming. As the list keeps growing, our
understanding of the mechanism of reprogramming will
go deeper and further. Novel modulators may provide
new important targets for small molecules that would
further increase the reprogramming efficiency in a safer
manner.
To optimize the transduction efficiency, the reprogram-
ing factors were initially delivered into cells using retro-
viral or lentiviral vectors that can be integrated randomly
into the genome [77]. Because the random integration of
Table 2 Small molecules that promote reprogramming
Compound Function Reference
Valproic acid histone deacetylase inhibitor [70]
Trichostatin A histone deacetylase inhibitor [70]
Sodium butyrate histone deacetylase inhibitor [70]
BIX-01294 histone methyl transferase inhibitor [89]
Parnate histone demethylase inhibitor [90]
5-azacytidine DNA methyltransferase inhibitor [74]
RG108 DNA methyltransferase inhibitor [89]
SB431542+ PD0325901 ALK5 inhibitor +MEK inhibitor [67]
A-83-01 TGFβ receptor inhibitor [92]
CHIR99021 GSK3 inhibitor [67]
RepSox Tgfbr1 kinase inhibitor [65]
PS48 activator of PDK1 [92]
Vitamin C nutrient vital that lower reactive
oxygen species
[93]









Sall4 increase the efficiency of
reprogramming
[57]
C/EBPα reprogramming of mature B cells [58]
UTF-1(ESC-specific
transcription factor )
increase the efficiency of
reprogramming
[59]
Cell signaling and proliferation









hTERT increase the efficiency of
reprogramming
[61]
TGFβ antagonist increase the efficiency
of reprogramming
[65-67]
Wnt3a increase the efficiency of
reprogramming
[68]
BMP4 replace Klf4 [64]
Epigenetic regulators
HDACs inhibition increase the efficiency
of reprogramming
[69-71]
G9a increase the efficiency of
reprogramming
[72]
DNMT1 inhibition promote fully
reprograming
[73,74]
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risk, significant effort was devoted to generate iPSCs with-
out any genetic modification. In this context, adenoviral
vector [78,79], plasmid vector [80] and minicircle [81],
episomal vectors [42,82,83], piggyBac transposon systems
[84,85], membrane-permeable reprogramming factors
[86,87], synthetic mRNA [88], MicroRNAs [63,75,76],
have been used to reprogram somatic cells into
integration-free iPSCs. However, the efficiency of these re-
programming technologies remains lower than the retro-
viral vector-based reprogramming approach [77]. This
problem could be partially mitigated by the identification
of small molecule chemical compounds that can signifi-
cantly improve the reprogramming efficiency (Table 2).
These compounds include the Valproic acid, trichostatin
A (TSA) and sodium butyrate, all histone deacetylase inhi-
bitors [70], BIX-01294, an inhibitor of histone methyl
transferase (HMT) [89], Parnate, a histone demethylase
inhibitor [90], 5-azacytidine (5-aza) and RG108, DNA
methyltransferase inhibitors [74,89]. All these chemicals
are epigenetic modifiers, indicating the importance ofepigenetic change during the reprogramming. Other small
molecule compounds, such as the antagonist of the trans-
forming growth factor β (TGFβ) pathway [67,91], the acti-
vator of the 3-phosphoinositide-dependent protein kinase
1 (PDK1) [92] and Vitamin C [93] can also dramatically
increase reprogramming efficiency. Therefore, the com-
bination of these chemical biology and integration-free
reprogramming strategies could significantly improve the
efficiency to generate integration-free iPSCs.
Bottlenecks of IPSCs
Genetic and epigenetic instability and immunogenicity
of iPSCs
When considering the clinic application of iPSC and
ESCs, iPSCs appear to have several advantages over
ESCs. For example, the generation of iPSCs avoids using
human embryos, a major ethic concern for the gener-
ation of hESCs. The cells derived from patient-specific
iPSCs are considered autologous cells and thus will not
be rejected by the patient’s immune system. In addition,
iPSCs derived from human patients offer the first oppor-
tunity to model human diseases with complex traits.
Recent studies, however, have raised the concern of the
safety of iPSCs in clinic application. While the global
gene expression profile of iPSCs is very close to ESCs,
there remains transcriptional signature that can distin-
guish between iPSCs and ESCs (Figure 1) [94]. Recent
studies have also identified significant epigenetic differ-
ences between iPSCs and ESCs. By comparing genetic-
ally identical ESCs and iPSCs, it has been shown that
expression levels for two genes (Gtl2 and Rian) and 21
miRNAs, all present on the imprinted Dlk1-Dio3 gene
cluster on Chromosome 12qF1, differ significantly.
Because of the developmental role of the Dlk1-Dio3 gene
cluster, these iPSCs contributed poorly to chimaeras and
Somatic cells iPS cells
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Figure 1 Genetic and epigenetic abnormalities in iPSCs. Induced pluripotency leads to genetic and epigenetic defects in iPSCs including
genomic DNA mutation, abnormal genomic DNA methylation and gene expression, copy number variation and chromosomal aneuploidy.
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plementation [95,96]. In addition, iPSCs appear to retain
some DNA methylation signatures of their somatic cells of
origin, called epigenetic memory [97,98]. The epigenetic
memory could potentiate the gene expression during the
iPSCs differentiation that favors the differentiation to the
original lineage, while restricting the differentiation poten-
tial to other lineages [98]. In addition, by whole-genome
profile of DNA methylation at the single-base resolution,
recent studies have shown that iPSCs harbor both epigen-
etic memory and aberrant DNA methylation [99].
Recent studies have shown that iPSCs also harbor gen-
etic mutations that are introduced during reprogramming
[100,101]. In addition, increased genetic abnormali-
ties such as copy number variation (CNV) [102,103],
chromosomal aberrations [104] are detected in iPSCs,especially in the early passages of iPSCs. While it remains
unclear how these genetic abnormalities impact on the
reprogramming efficiency, some of the gene mutations
are associated with human cancers [100]. Therefore, the
cells derived from iPSCs could have increased cancer risk.
In support of this notion, chimeric mice and tetraploid
complemented mice generated with iPSCs reprogrammed
with Oct4/Sox2/Klf4/c-Myc in viral vectors are highly
susceptible to tumorigenesis [40,105]. The cancer risk
associated with integration-free iPSCs remains to be
examined, especially when the highly oncogenic c-Myc
and Klf4 are left out of the reprogramming cocktail.
While it has been generally assumed that autologous cells
derived from patient-specific iPSCs should be immune tol-
erated by the patient, it is possible that the genetic and epi-
genetic abnormalities of iPSCs could contribute to minor
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shown that transplantation of iPSC-derived cells could
ameliorate disease phenotypes in mouse models without
apparently immune rejection [106,107]. However, these
studies were carried out in either immune privileged site or
in lethally irradiated mice. Taking advantage of the capabil-
ity of iPSCs to form teratomas that contain all lineages of
cells in the body, recent studies have demonstrated that,
unlike ESC-derived cells that are not immunogenic in syn-
geneic hosts, some cells derived from iPSCs are immuno-
genic in the syngeneic recipients due to the abnormal
expression of minor antigens in some cells in the teratomas
during the differentiation of iPSCs (Figure 2) [42]. While
remaining to be confirmed, the abnormal overexpression of
the minor antigens might be due to the abnormal epigenet-
ics of iPSCs. In addition, the contribution of the coding
sequence mutations to the immunogenicity of iPSC-derived
cells remains to be examined.
Checkpoints in induced pluripotency
Induced pluripotency by defined factors is a very ineffi-
cient process. A series of studies indicate that critical
tumor suppressors such as p53 and ARF are major check-
points in suppressing induced pluripotency (Figure 3)
[108]. The critical tumor suppression activity of p53 is
underscored by the finding that p53 is inactivated in most
human cancers either by gene mutation or the disruption
of pathways required for p53 activation [109]. p53 is a
transcription factor that directly regulates the expression
of hundred of genes. For example, p53 directly activates
the expression of genes involved in cell cycle arrest (p21,







Figure 2 The Immunogenicity of iPSC derivatives. The abnormal overex
iPSC-derived cells leads to the antigen-specific T cell activation. APC, antige
receptor.and suppresses the expression of genes such as MAP4 and
Nanog [110]. In addition to p53-dependent transcription,
p53 also plays important transcription-independent roles
in physiological processes such as metabolism [111] and
miRNA processing [112].
In the absence of any stresses, p53 is inactive and
unstable. Once activated in response to genotoxic and
oncogenic stresses, p53 induces cell cycle arrest, apoptosis,
or senescence in somatic cells [113,114]. In ESCs, p53 plays
a unique role in maintaining their genome stability. Upon
DNA damage, p53 suppresses the expression of the pluri-
potency factor Nanog and thus induces the differentiation
of ESCs harboring DNA damage [115]. This mechanism
ensures that the self-renewing ESCs harbor no DNA dam-
age, and thus are genetically stable. In support of an
important role of p53 in maintaining genomic stability in
ESCs, p53-deficient human ESCs exhibit extensive genomic
instability [116]. The role of p53 in suppressing Nanog
expression could also account for the findings that the
silencing of p53 at the late stages of reprogramming of
iPSCs increases the reprogramming efficiency because
Nanog is important to promote the transition from pre-
iPSCs to stable iPSCs [117]. It is also consistent with earlier
findings that p53 is activated during ESC differentiation to
inhibit the dedifferentiation by suppressing the Nanog
expression [118].
In addition to c-Myc and Klf4 that are well-established
oncogenes, other reprogramming factors including Oct4,
Sox2, Nanog and Lin28 appear to have oncogenic poten-
tial [77]. In this context, Oct4, Sox2 and Nanog are fre-
quently overexpressed in many types of human cancers
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Figure 3 Tumor suppressor p53 inhibits induced pluripotency. p53 is activated by oncogenic stresses and DNA damage during
reprogramming, leading to cell cycle arrest, apoptosis, or senescence, which all limit successful reprogramming. Upon activation, p53 also
suppresses the expression of Nanog that is required for the transition from pre-iPSCs to iPSCs.
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reprogramming factors can activate p53 [114]. In support
of this notion, ARF, which is responsible for activating p53
in response to oncogenic stresses, also suppresses induced
pluripotency [124-126]. In addition, the DNA double-
stranded break damage induced during reprogramming, a
potential outcome of oxidative stresses, can also activate
p53 [124]. In support of this notion, DNA damage-
induced activation of p53 is important to suppress
induced pluripotency [127]. The activation of p53 leads to
cell cycle arrest, apoptosis and senescence, any of which
can block successful reprogramming. Therefore, p53
might be inactivated at least temporarily for the successful
iPSC reprogramming. MdmX functions as an E3 ligase of
p53, thus negatively regulates p53 activity. Stabilization ofMdmX by mutation of three serine residues to alanines
(Mdmx Ser 341, Ser 367 and Ser 402) dramatically
decreases p53 activity and increases reprogramming effi-
ciency [126] (Figure 3). Consistent with this notion, transi-
ent silencing of p53 can significantly increase the
reprogramming efficiency [83,124,128] and recent studies
have shown that Vitamin C can increase the reprogram-
ming efficiency partly by inhibiting the ARF/p53 activation
during reprogramming [129]. While the impact of the
transient silencing of p53 on the genomic stability of
iPSCs remains to be examined, the iPSCs derived from
p53 null cells exhibit extensive genomic instability [128].
p53 plays multiple roles in tumor suppression. There-
fore, it is important to understand which p53-dependent
function is involved in suppressing induced pluripotency.
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cell cycle arrest [130], increases the reprogramming effi-
ciency, indicating that p53-dependent cell cycle arrest is
involved in suppressing induced pluripotency. The
involvement of p53-dependent apoptosis in suppressing
induced pluripotency is more complex. Puma, which is
required for p53-dependent apoptosis after genotoxic
stresses, is involved in suppressing induced pluripotency
only when c-Myc is left out of the reprogramming cock-
tail [127]. This could be due to the findings that c-Myc
significantly reduces the levels of oxidative stresses
during the reprogramming [93], and high levels of
oxidative stresses induce p53-dependent apoptosis [131].
Interestingly, in contrast to the greatly increased
reprogramming-induced DNA damage in p53-deficient
cells, the reprogramming-induced DNA damage in
Puma-/-p21-/- cells is the same as the wild-type cells
due to the increased senescence [127]. This raises the
possibility that the transient silencing of Puma and p21
can increase the reprogramming efficiency of iPSCs
without promoting genetic instability.
Future perspective
While significant progress has been achieved to improve
the reprogramming efficiency of iPSCs and reduce their
cancer risk with new approaches to generate integration-
free iPSCs, recent discoveries of the epigenetic and genetic
abnormalities in iPSCs and the surprising immunogenicity
of iPSC derivatives have raised safety concerns for clinic
development of iPSCs. Considering the critical roles of
p53 in maintaining genomic stability, it is important to
elucidate which p53-dependent functions are involved in
suppressing induced pluripotency. The acquired informa-
tion can help to develop new strategy to retain the tumor
suppression activity of p53 during the reprogramming into
induced pluripotency. In addition, the reprogramming
approach needs to be optimized to eliminate the com-
ponents from the reprogramming cocktail that are
involved in p53 inactivation. It is also important to
resolve the bottleneck associated with the epigenetic
abnormalities of iPSCs. Based on the findings that the
epigenetics of the pluripotent stem cells generated by
SCNT are more similar to ESCs [98], it is possible to
optimize the reprogramming strategy to minimize the
epigenetic difference between iPSCs and ESCs. In this
context, small molecule compounds that can promote
reprogramming efficiency by targeting epigenetic enzymes
could help to achieve this goal. The overcome of these
bottlenecks could also reduce the immunogenicity of
iPSC-derived cells and improve the feasibility to
develop iPSC-based human therapy.
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